EP1242608A2 - Verfahren zur erreichung einer persistierenden transgenexpression - Google Patents

Verfahren zur erreichung einer persistierenden transgenexpression

Info

Publication number
EP1242608A2
EP1242608A2 EP00991274A EP00991274A EP1242608A2 EP 1242608 A2 EP1242608 A2 EP 1242608A2 EP 00991274 A EP00991274 A EP 00991274A EP 00991274 A EP00991274 A EP 00991274A EP 1242608 A2 EP1242608 A2 EP 1242608A2
Authority
EP
European Patent Office
Prior art keywords
composition according
nucleic acid
inflammatory
expression
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00991274A
Other languages
English (en)
French (fr)
Inventor
Patrick Lu
David Leonard Ennist
Mervat Mina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of EP1242608A2 publication Critical patent/EP1242608A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to non-inflammatory vector composition, as well as method of treating a patient suffering from a disorder having an inflammatory component
  • the lung is an attractive target for gene therapy methodologies due to its accessibility and large surface area.
  • Existing techniques suffer from certain failings.
  • ex vivo gene therapy for pulmonary diseases involving implantation into the tracheal epithelium has been studied experimentally, but faces challenges in transitioning to the clinic.
  • this type of therapy requires the permanent genetic modification of a stable, self-renewing cell population capable of giving rise to the other cell types of the epithelium.
  • the existence of such a stem cell for the pulmonary epithelium remains controversial to this day.
  • An alternative ex vivo approach involves transplantation of gene-modified cells at a site distal to the lung to obtain serum secretion of a protein that is therapeutically relevant to pulmonary disease.
  • Several studies have been reported using cells transplanted in the liver or the peritoneum bearing a transgene encoding ⁇ i-antitrypsin, a deficiency of which causes familial emphysema. Kay, et al., Proc. Natl. Acad. Sci. USA 89: 89-93 (1992); Garver, et al., Science 237: 762-64 (1987).
  • Low-level transient expression was observed.
  • ⁇ i-antitrypsin must reach a concentration of greater than 1 mg/ml in the serum in order to have a therapeutic effect by diffusion into the lung. This level of expression is beyond the capabilities of the best vectors currently available.
  • ex vivo approaches require use of syngeneic cells in order to avoid immunological rejection of the transplant. Accordingly, such methods are highly individualized and require a significant amount of tissue culture per patient. The ex vivo approach is thus both labor intensive and technically very demanding.
  • in vivo gene therapy products for the lung that can be directly administered to the patient are more readily incorporated into the current medical and pharmaceutical infrastructure.
  • most cystic fibrosis gene therapy products under development are designed for delivery by aerosol based systems similar to those currently in clinical use for the administration of a number of conventional pulmonary medicines. Martin, et al., Hum. Gene Ther. 9: 87-114 (1998).
  • many of the technical, medical and commercial underpinnings that must be developed for the successful introduction of ex vivo gene therapies already are in place for in vivo gene therapies.
  • in vivo systems have relied on viral delivery systems, but there is substantial interest and effort directed toward developing synthetic vector compositions, due to shortcomings associated with viral vectors.
  • adenoviruses seem a good choice for a pulmonary delivery system. They are trophic for the respiratory epithelium and have a relatively large coding capacity.
  • the NIH Recombinant DNA Advisory Committee (RAC) approved the first three clinical gene therapy protocols for cystic f ⁇ brosis, all of which were adenoviral based.
  • the initial enthusiasm over adenoviral vectors has since been tempered by the realization that host responses severely limit the utility of this vector system.
  • immediate inflammatory responses limit initial tra ⁇ sduction efficiencies
  • alveolar macrophages rapidly eliminate adenoviral vectors
  • CTL cytotoxic T lymphocyte
  • AAV adeno-associated virus
  • VIROLOGY Fields, B.N. et al., eds
  • the virus is able to integrate into the genome of human cells at a unique site on chromosome 19, but the location and extent to which vectors derived from AAV integrate remains problematic.
  • Expression of human CFTR six months following AAN- mediated gene transfer has been detected in rabbits (Flotte et al., Proc. Natl. Acad. Sci.
  • the viral coding sequences are generally provided in trans from a helper plasmid, and the plasmids are cotransfected into adenovirus infected cells to produce quantities of the AAV vector.
  • Lentiviruses are positive-strand RNA viruses that utilize reverse transcriptase to convert their genome into a double-stranded DNA provirus that inserts into the genome of the infected cell. Narayan et al, in VIROLOGY (Fields et al, eds), pp. 1679-1721 (1990). Unlike traditional retroviral vectors, (Miller et al, Mol. Cell. Biol. 10: 4239-42 (1990)), lentiviral vectors are able to infect nondividing cells, (Naldini, et al, Science 272, 263-67 (1996); Miyake et al, Hum. Gene Ther.
  • Synthetic vectors employ a complex of nucleic acid, usually in the form of a plasmid, with molecules that facilitate the delivery of the nucleic acid to target cells.
  • synthetic vectors should have lower toxicity and lower immunogenicity.
  • Synthetic vectors have several potential advantages: They do not have an upper size limit to the D ⁇ A that can be packaged, are not infectious, are easier to manufacture and QC in large quantities, and are made up of well-defined components. Thus, the primary rationale for pursuing synthetic vector systems is to avoid the known problems of viral systems. Two main classes of synthetic vectors have proven to be useful in delivering genes in vivo, where D ⁇ A is complexed with cationic lipids or cationic polymers, respectively.
  • Plasmid D ⁇ A complexed with cationic lipids has been successfully used to transfect lung cells in vivo by both intravenous and tracheal administration.
  • Cationic polymers similarly interact with D ⁇ A by electrostatic interactions.
  • Polylysine has been conjugated to ligands that allow receptor-mediated delivery of the complex to specific target cells.
  • Polyethyleneimine (PEI) is a cationic polymer that has shown some recent promise. This cationic polymer has been found to be an efficient vector for in vivo transduction of mouse lungs, either by the oral-tracheal or intravenous routes. Ferrari et al, Gene Ther. 4, 1100-1106 (1997); Goula et ⁇ /., Gene Ther. 5, 1291-1295 (1998). The majority of in vivo animal studies using synthetic vectors have relied on
  • the invention provides a composition containing a free DNA vector encoding a transgene, an enhancing agent (like a surfactant) and/or an antiinflammatory agent, (like a steroid).
  • a composition containing a free DNA vector encoding a transgene, an enhancing agent (like a surfactant) and/or an antiinflammatory agent, (like a steroid).
  • This composition when administered to a patient, is capable of eliciting significant levels of transgene expression, without a limiting immune response, which makes them particularly suitable for treating inflammatory disorders.
  • the composition is administered repeatedly, typically at intervals exceeding forty-eight hours.
  • the transgene is a protease inhibitor, which can act on a variety of proteases, including neutrophil elastase, cathepsin G, collagenase, proteinase 3, plasminogen activator.
  • the invention provides compositions and methods suitable to obtain therapeutically effective levels of transgene-encoded products sufficient to treat patients suffering from pulmonary disorders such as emphysema, chronic obstructive pulmonary disease, cystic fibrosis, adult respiratory distress syndrome and asthma, and other disorders with an inflammatory component, like arthritis.
  • Figure 1 demonstrates sustained high levels of transgene expression using the inventive compositions and methods.
  • Figure 2 demonstrates in vivo distribution of a secreted protein following oral- tracheal instillation of a plasmid carrying the cDNA of the secreted protein.
  • the invention is directed to methods and compositions for achieving persistent expression of a therapeutic gene product.
  • the therapeutic gene product typically is a protein, but may also be a nucleic acid such as an antisense or ribozyme agent.
  • the compositions and methods described herein do not elicit a limiting inflammatory or immune response, and this property allows for repeated nucleic acid administration without significantly reduced expression levels.
  • the invention provides new and improved methods of delivering a nucleic acid to the lungs or joints of an animal.
  • the nucleic acid encodes a gene whose expression is controlled by other elements contained within the same vector that contains the nucleic acid.
  • the present methods and compositions are useful in any situation, including clinical situations, where persistent transgene expression is desired. They are especially suited to situations requiring persistent expression in the lungs or joints. For example, they are useful in human gene therapy applications. It will be understood, however, that they may also be used in veterinary (non-human animal) applications, especially for mammals. They are also useful in generating experimental animal models of transgenes.
  • compositions suitable for delivering a transgene are composed of a nucleic acid such as DNA, encoding at least one gene of interest ("transgene")-
  • a enhancing agent such as a surfactant, and/or a steroid.
  • the vector portion of the composition does not significantly exacerbate an inflammatory condition in the lung or joints. In other words, the vector does not induce a substantial inflammatory response, which would be counter to treating inflammatory disorders. Characteristics of the inflammatory response are provided below.
  • One preferred form of such a composition contains a nucleic acid lacking CpG islands that activate or enhance activation of lymphoid cells.
  • These compositions may be used, for example, in the treatment of respiratory disease, particularly asthma and chronic obstructive pulmonary disease (COPD) or in the treatment of arthritic disease, such as rheumatoid arthritis and osteoarthritis.
  • COPD chronic obstructive pulmonary disease
  • the DNA used in the present compositions can be plasmid-based.
  • Such vectors are conveniently propagated in bacteria, like E. coli. However, when bacterial propagation is used, it is preferable to use purification methodologies that result in efficient endotoxin removal, since endotoxin may interfere with persistent transgene expression, likely by promoting an inflammatory response. While the vector is preferably supercoiled, for maximum transgene expression it may also be relaxed or even linearized. The artisan is well apprised of methods for generating and propagating such vectors.
  • the vectors used in the invention contain the features that are characteristic of plasmid vectors. These include, for example, an origin of replication suitable for propagation in a host.
  • An origin of replication suitable for propagation in a host is the ColEl origin, which can exist as the relatively low copy number version present in pBR322 or the higher copy number version present in the pUC series of vectors and other conventional vectors.
  • the vectors also generally contain a selectable marker to ensure that a transformed host cell retains the vector. Common examples may confer ampicillin resistance, puromycin resistance, tetracycline resistance, kanamycin resistance, rifampicin resistance or spectinomycin resistance. The skilled artisan will be aware that other selectable markers, including markers that will be developed in the future, can be used.
  • the vectors contain all of the cis elements needed for effective transcription and translation of the encoded transgene. These elements will be operatively linked to the transgene so as to facilitate transgene expression. Such elements, such as promoters, are well known to the artisan. Exemplary promoters may be strong constitutive promoters, may be tissue-specific, inducible or have any other known desirable characteristic.
  • free nucleic acid is defined as an aqueous solution of nucleic acid, typically DNA, RNA, or synthetic analogues. Nucleic acids are typically prepared by biological propagation of constructs that are isolated, purified, and in some cases modified synthetically from a plasmid or viral source. Conventional viral vectors, such as recombinant retroviruses, lentiviruses, adenoviruses and adeno-associated viruses, are not included within this definition. Importantly, free nucleic acids do not induce an expression-limiting immune response; and do not exacerbate, for example, a pulmonary or intra-articular inflammatory condition. The free nucleic may be an RNA, but DNA molecules are preferred due to their superior stability.
  • a particular embodiment of the invention provides methods of using forms of nucleic acids that produce therapeutic activity through the expression of antisense or ribozyme constructs.
  • forms of nucleic acids are used that produce therapeutic activity without requiring expression by the cells of the lung or the joint.
  • the nucleic acids themselves may be active directly, as is the case with antisense and catalytic nucleic acid molecules.
  • compositions may contain an "enhancing agent" that improves the pharmacology of the nucleic acid composition within the tissues of the lung or joint, (e.g. distribution and persistence), resulting in improved therapeutic activity of the nucleic acid.
  • an "enhancing agent” that improves the pharmacology of the nucleic acid composition within the tissues of the lung or joint, (e.g. distribution and persistence), resulting in improved therapeutic activity of the nucleic acid.
  • One preferred enhancer is a natural or biological surfactant.
  • Surfactants are surface-active amphipathic compositions that have surface tension-lowering properties
  • the surfactants useful in the invention are safe for pulmonary administration. Such surfactants, both synthetic and natural, are well known in the art and several are commercially available.
  • Survanta Beractant, available from Ross Laboratories
  • Exosurf colfosceril palmitate, available from Glaxo Wellcome
  • Infasurf calfactant, available from Forest Laboratories
  • surfactants which lower the surface tension, thus facilitating the dispersion of the vector.
  • Naturally occurring surfactants are a complex mixture of phospholipids, neutral lipids, fatty acids and proteins.
  • Surfactants are amphipathic in nature, having polar as well as nonpolar components and, thus, permit interactions between aqueous and lipidic fluids.
  • Survanta a preferred surfactant, is a semi-synthetic surfactant derived from cow lung. It contains naturally-occurring lipids, fatty acids, and the surfactant-associated proteins SP-B and SP-C. This mixture is supplemented with additional fatty acids to provide a standardized preparation. Survanta is approved for clinical use in treating infant respiratory distress syndrome (RDS). A typical dose is 4 cc/kg intratracheally and up to 4 doses, given 6-12 hours apart, are used. Similar dosing regimens are suitable for use in the present invention, though methods of determining alternative dosing regimens are known to those of skill in the art.
  • RDS infant respiratory distress syndrome
  • Some enhancing agents are synthetic or semi-synthetic surfactants. Such enhancers can be amphipathic synthetic or semi-synthetic polymers, lipids, and fluorocarbons.
  • a suitable class of synthetic polymer surfactant is PluronicTM surfactants.
  • One synthetic lipid surfactant is an anionic liposome formulation (Bangham, et al, Chem-Phys-Lipids. 64: 275-85 (1993), Bangham, et al, Lung. 165: 17-25, (1987)).
  • Other lipid surfactants are surfactant polymer-lipid conjugates. Suitable such conjugates include ThesitTM, Brij 58TM, Brij 78TM, Tween 80TM, and Chol- PEG 900.
  • Hyalgan a preferred form of hyaluronic acid, is a viscous solution of a high molecular weight fraction of purified natural sodium hyaluronate in buffered physiological saline. It is approved for clinical use for the treatment of pain in osteoarthritis of the knee. A typical dose is 20 mg administered by intra-articular injection once a week for a total of five injections. Similar dosing regimens are suitable for use in the present invention, though methods of determining alternative dosing regimens are known to those of skill in the art.
  • Still other enhancing agents permit improved contact with target cells in deep airways and in structural regions or throughout the joint capsule once the nucleic acid has reached the tissue.
  • Such enhancers can be electrically neutral, amphipathic polymers.
  • One suitable electrically neutral, amphipathic polymer is polyoxazoline.
  • Yet other enhancing agents permits persistence of the nucleic acid extracellularly in the deep airways and within the joint capsule and in structural regions thereby enhancing persistence of therapeutic activity. Such enhancers reduce metabolic processes and clearance of the nucleic acid from the tissues of the lung or joint.
  • compositions contain an ant ⁇ nflammatory agent, such as a steroid, that can effectively suppress or alleviate one or more aspects of an inflammatory response, including mononuclear cell infiltration, edema, release of chemokines and other pro-inflammatory mediators.
  • an ant ⁇ nflammatory agent such as a steroid
  • Inhaled steroids for the lung or intra-articular steroid injections are particularly preferred in this regard.
  • the anti-inflammatory agents can be administered systemically, for example via oral administration or intravenous administration.
  • examples include dexamethasone and hydrocortisone.
  • the ant ⁇ nflammatory compound may also be a non-steroidal anti-inflammatory agent (an NSAID).
  • NSAIDs include COX2 inhibitors (e.g., CELEBREX, conventional dose 200 mg/day) and Tilade .
  • Useful dosages are based on those conventionally used in the art. Frequency of administration also is informed by the art, but will generally be guided by how often the nucleic acid vector is administered. It is understood that any compounds described herein contemplate, where applicable, any free acids, free bases, esters, as well as pharmaceutically acceptable salts thereof. Reference to one form, should be read as contemplating all forms, unless otherwise noted.
  • a typical method entails administering to a patient an effective amount of a composition comprising a free nucleic acid vector, such as a DNA plasmid, in combination with an enhancer and/or an ant ⁇ nflammatory compound.
  • the vector encodes a transgene of interest, and the methods result in effective transgene expression.
  • an effective amount of expression is one that is therapeutically significant, meaning that there is some measurable effect on the disease itself, symptoms and/or some underlying pathological marker. Such effects may be qualitative or quantitative, and the clinician will be familiar with each marker as it relates to different conditions being treated. For example, decreased IL8 or neutrophils in the bronchoalveolar fluid of COPD patients would be indicative of a therapeutic effect.
  • Surfactants and other enhancing agents useful in the inventive methods may be obtained commercially.
  • suitable surfactants include, but are not limited to, Survanta (Beractant, available from Ross Laboratories), PluronicTM, TweenTM, and BrijTM.
  • Survanta has been shown to suppress mitogen-induced lymphocyte proliferation (Kremlev et al, Am. J. Physiol. 267:L357-64 (1994)), and may thus aid in this process.
  • Other surfactants may have sim ⁇ ar beneficial properties.
  • the nucleic acid-containing composition may be de ⁇ vered, for example, as a dry powder or as a liquid suspension by any suitable means that results in pulmonary administration.
  • the composition may be inhaled (e.g., as an aerosol), instilled in the lung and/or administered tracheally.
  • these methods of administration may be used independently or in combination, as particular circumstances require.
  • other methods of pulmonary administration may be used, including methods that are developed in the future.
  • the transgene-containing composition may be de ⁇ vered as a liquid suspension, or other physiologically compatible form, by any suitable means that results in intra-articular administration.
  • the composition may be directly injected into the joint or injected intravenously and targeted to the inflamed joint.
  • these methods of administration may be used independently or in combination, as particular circumstances require.
  • other methods of articular administration may be used, including methods that are developed in the future.
  • a key feature of the present methods is persistent expression of the nucleic acid activity, e.g. transgene expression.
  • gene therapy methods have been limited by immune and inflammatory responses, which (1) reduced overall nucleic acid activity, in this case transgene expression and (2) prevented the use of re-administration as a method of boosting expression.
  • transgene expression did not persist.
  • Expression is "persistent" where it does not decrease substantially over time, either as a result of a single dose or multiple administrations. Usually, therefore, effective levels of expression are maintained.
  • expression levels do not decrease to less than 25% of the maximal level in between administrations, and more preferably not less than about 50%, but in some instances it is beneficial to go below these thresholds, such that the a dose "pulsing" is accomplished with repeated administration.
  • a preferred method involves administering the free nucleic acid vector compositions on two or more occasions. In this manner, nucleic acid activity may be boosted or restored to levels approximating the level obtained following the initial administration so that effective levels of nucleic acid activity are maintained. Because the present methods do not trigger a limiting immune or inflammatory response, the compositions of the invention may be administered as many times as needed to maintain effective levels of activity.
  • administration is accomplished every few days, but more typically it is done weekly, and some may involve biweekly or monthly administration. Using such methods, a decrease in activity between administrations may be observed, depending on the condition being treated. These methods are still considered to induce "persistent" activity because, unlike prior art methods, the present compositions can be re-administered repeatedly, without a substantial decrease in transgene expression, relative to the previous dose. Typical methods entail repeated administration for at least about a month, but may entail longer periods of treatment. In another embodiment, the inventive method further entails administering an ant ⁇ nflammatory compound, such as a steroid or an NSAID, that has the ability to mitigate a subject's inflammatory response.
  • an ant ⁇ nflammatory compound such as a steroid or an NSAID
  • ant ⁇ nflammatory compound in general, it is useful to administer the ant ⁇ nflammatory compound prior to administering the vector/enhancer composition, but they may be administered together. Suitable ant ⁇ nflammatory compounds are described above.
  • the ant ⁇ nflammatory agent typically is admmistered by intravenous or oral route, and may be included in the nucleic acid composition, or used as a separate drug.
  • the therapeutic app ⁇ cation of the present methods extends to pulmonary and non-pulmonary disorders, including rheumatoid arthritis and osteoarthritis. As indicated above, the lungs are an attractive target for nucleic acid de ⁇ very due to their large surface area and relative ease of access. Thus, the present methods are adaptable to the gene therapy-based treatment of any (pulmonary or non-pulmonary) disorder where therapeutic levels of transgene expression are obtained.
  • the artisan is well versed in such appkcations. For example, Brigham et al, Nature 362: 250-55 (1993), expressed human growth hormone (hGH) following administration of a plasmid encoding the cDNA and Cannizzo et al, Nature Biotech. 15: 570-73 (1997), increased blood platelet counts following instillation of an adenoviral vector expressing thrombopoietin in the lungs of experimental animals.
  • hGH human growth hormone
  • the present methods are especially suited to treat disorders of the lung and conditions that have pathological manifestations hi the lung.
  • the methods are suited for treatment of diseases with inflammatory pathologies and etiologies.
  • exemplary disorders include, but are not limited to, emphysema, COPD, cystic fibrosis (CF), adult respiratory distress syndrome (ARDS), pulmonary fibrotic syndromes and asthma.
  • CF results from a deficiency in the cystic fibrosis transmembrane regulator (CFTR), a cAMP-activated chloride channel.
  • CFTR cystic fibrosis transmembrane regulator
  • the respiratory manifestations predominate and death results from progressive respiratory failure in greater than 95% of cases.
  • This protein which normally provides much of the antiprotease protection for the lung, is produced in the liver and reaches the lung by diffusion from the serum.
  • this gene will provide effective therapy for familial emphysema and other inflammatory conditions of the lung where the antiprotease defenses are either nonexistent or have been overwhelmed.
  • a vector that directly transduces the pulmonary epithe ⁇ um must avoid exacerbating this condition.
  • a suitable vector rather than being injectable, could be aerosolized, and the promoter, without being required to be as strong as the endogenous natural Uver promoter, preferably is both tissue-specific and constitutively expressed.
  • SLPI secretory leukoprotease inactivator
  • Suitable SLPI proteins include the following:
  • SEQ ID No. 1 (native mature form): SGKSFKAGVC PPKKSAQCLR YKKPECQSDW QCPGKKRCCP DTCGIKCLDP VDTPNPTRRK PGKCPVTYGQ CLMLNPPNFC EMDGQCKRDL KCCMGMCGKS CVSPVKA
  • SEQ ID No. 2 (native immature form): MKSSGLFPFL VLLALGTLAP
  • SEQ ID No. 3 (oxidation-resistant mature form): SGKSFKAGVC PPKKSAQCLR YKKPECQSDW QCPGKKRCCP DTCGIKCLDP VDTPNPTRRK PGKCPVTYGQ CLLLNPPNFC EMDGQCKRDL KCCMGMCGKS CVSPVKA
  • SEQ ID No. 4 (oxidation-resistant immature form): MKSSGLFPFL VLLALGTLAP WAVEGSGKSF KAGVCPPKKS AQCLRYKKPE CQSDWQCPGK KRCCPDTCGI KCLDPVDTPN PTRRKPGKCP VTYGQCLLLN PPNFCEMDGQ CKRDLKCCMG MCGKSCVSPV KA
  • a particularly useful class of nucleic acid is one which contains a transgene encoding a protease inhibitor.
  • exemplary protease ⁇ hibitors may inhibit the activity of proteases such as neutroph ⁇ elastase, cathepsin G, collagenase, proteinase 3 and plasminogen activator.
  • proteases such as neutroph ⁇ elastase, cathepsin G, collagenase, proteinase 3 and plasminogen activator.
  • proteases such as neutroph ⁇ elastase, cathepsin G, collagenase, proteinase 3 and plasminogen activator.
  • proteases such as neutroph ⁇ elastase, cathepsin G, collagenase, proteinase 3 and plasminogen activator.
  • proteases such as neutroph ⁇ elastase, cathepsin G, collagenase, proteinase 3 and plasminogen activator
  • Protease inhibitors useful in the inventive methods and compositions include ⁇ i-antitrypsin, Secretory Leukocyte Protease Inhibitor (SLPI), ⁇ l-antichymotrypsin, tissue inhibitors of metalloprotease ("TLMPs", like TTMP-1, -2 and -3), elafin and ⁇ 2- macroglobuUn.
  • SLPI Secretory Leukocyte Protease Inhibitor
  • TLMPs tissue inhibitors of metalloprotease
  • Some (ctrantitrypsin and SLPI, for example) of the foregoing protease inhibitors are inactivated via an oxidative mechanism.
  • they have a sulfhydryl-containing arnino acid (e.g., cysteine), which must be in reduced form for maximal activity.
  • oxidation resistant analogs may be prepared that lack such residues. It is anticipated that such oxidation-resistant (and, hence, inactivation-resistant) protease inhibitors will have improved pharmacodynamic properties, such as increased half-life.
  • the transgene sequence for expression can be modified to generate a protein with altered or new peptide sequences that have beneficial effects on the pharmacology of the protease inhibitor.
  • the transgene for a protease inhibitor is modified to produce a chimeric protein with aU or part of a natural or engineered unmunoglobin sequence. The binding activity of the unmunoglobin portion permits enhanced binding to tissue regions of interest and enhanced persistence at those tissue regions. Other peptide sequences can be used in place of the Unmunoglobin sequence that permit retention in the tissue or protection from metabohc processes in the tissue.
  • Anti-oxidant therapies for lung diseases employ, for example, superoxide dismutase or catalase. These antioxidant therapies are also useful generally in treating inflammatory conditions, since inflammation results in the activation of oxidative processes (e.g., myeloperoxidase), and the subject antioxidants w ⁇ l neutralize the resulting reactive oxygen species.
  • nucleic acids that inhibit disease processes.
  • the nucleic acid inhibits production of natural proteases. This can be through expression of antisense or ribozyme constructs or through direct inhibition of cells producing the protease.
  • the invention encompasses such variation, in the form of derivatives or variants, which terms are used interchangeably herein, and specificaUy include oxidation-resistant forms of protease inhibitors.
  • sequence identity refers to a comparison made between two molecules using, for example, the standard Smith- Waterman algorithm that is weU known in the art. Some derivatives wiU have at least about 50%, 55% or 60% identity. Preferred molecules are those having at least about 65% sequence identity, more preferably at least 65% or 70% sequence identity. Other preferred molecules have at least about 80%, more preferably at least 80% or 85%, sequence identity. Particularly preferred molecules have at least about 90% sequence identity, more preferably at least 90% sequence identity. Most preferred molecules have at least about 95%, more preferably at least 95%, sequence identity. As used herein, two nucleic acid molecules or proteins are said to "share significant sequence identity” if the two contain regions which possess greater than 85% sequence (amino acid or nucleic acid) identity.
  • Sequence identity is defined herein with reference to the BLAST 2 algorithm using default parameters. See Altschul et al, J. Mol Biol 215:403-410 (1990); Gish, Nature Genet. 3:266-272 (1993); Madden, Meth. Enz mol 266:131-141 (1996); Altschul et al, Nucleic Acids Res. 25:3389-3402 (1997); and Zhang et al, Genome Res. 7:649-656 (1997).
  • the BLAST 2 algorithm also is ava ⁇ able at the NCBI (http://www.ncbi.nUn.nih.gov/BLAST).
  • a therapeuticaUy effective amount of transgene expression or nucleic acid activity is an amount that substantially inhibits an adverse inflammatory response.
  • inventions of the method for treating inflammatory conditions include treatments of arthritis.
  • one method is the expression of transgenes that protect the cartilage from proteases resulting from undesired mflammation in the joints.
  • the method can be used for deUvery of nucleic acid constructs that exert an activity which diminishes one or more steps in the undesired inflammation in joints.
  • Other embodiments of the method are for the treatment of undesired or excessive inflammation in other tissues and pathologies.
  • An example of an inflammatory disorder of the lungs that is treatable according to the present methods is asthma. Asthma involves a complex cascade of inflammatory mediators, any of which is a target for therapeutic intervention.
  • Asthma is characterized predominantly by the presence of TH2-like T-ceUs, producing IL-4 and IL-5, but not IL-2 or IFN- ⁇ .
  • the C-C-chemokines which include RANTES, MCP-3, MCP-4, Eotaxin and Eotaxin-2.
  • certain cytokines are known to counteract the TH2-driven uiflammatory response, including IL-12, IFN- ⁇ , IFN- ⁇ , IL-10, and TGF- ⁇ .
  • the range of targets for the treatment of inflammatory pulmonary disorders includes, but is not limited to, IL-4, IL-5, RANTES, MCP-3, MCP-4, Eotaxin, Eotaxin-2, IL-12, IFN- ⁇ , IFN- ⁇ , IL-10, and TGF- ⁇ .
  • IL-10 is considered a general immunosuppressor that inhibits IFN- ⁇ and IL-2 production by TH2 cells, as weU as a variety of other immune responses.
  • Wh ⁇ e IL-10 is a somewhat general immune mediator, IL-5 is more specific.
  • IL-5 is the major, and perhaps the only, cytokine involved in eosinophiUa, which makes it a particularly attractive point of therapeutic intervention in eosinophiUc diseases, such as aUergy and asthma.
  • preferred therapeutic targets also include IL-10 (see, e.g., GenBank Ace. Nos. U91746, U 16720 and X78437 for IL-10, and 4504632 and U00672 for the IL-10 receptors) and IL-5 (see, e.g., GenBank Ace. Nos. J03478 and M33949 for IL-5, and A26251 and A26249 the IL-5 receptor).
  • the foregoing inflammatory mediators may be inhibited by a variety of agents that can be encoded in a gene therapy vector.
  • genes encoding specific antibodies, and especiaUy antibody fragments may be cloned into such a vector.
  • soluble forms of the receptors may be encoded in the vector.
  • two naturally-occurring forms of the IL-5 receptor (“LL-5R”) exist: one is membrane bound and the other is soluble. The soluble form inhibits the binding of IL-5 to the membrane form, thereby antagonizing the biological activity of IL-5.
  • soluble LL-5R is a preferred ant ⁇ nflammatory medicament.
  • inhibitors such as antisense nucleic acids and ribozymes also may be employed.
  • treating in its various grammatical forms as used in describing the present invention refers to preventing, curing, reversing, attenuating, aUeviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease causative agent or other abnormal condition.
  • the plasmid used was pCHuc, which contains the firefly luciferase gene under the control of the cytomegalovirus promoter.
  • Female BALB/c mice (6-8 weeks old) were obtained from Harlan Sprague Dawley (IndianapoUs, IN). Mice were anesthetized by placing them in a beU jar containing 5% isoflurane. The DNA was appUed to the lungs by oral tracheal instiUation using an angled feeding needle. Twenty four hours after administration, the animals were sacrificed, and the lungs were removed and placed on dry ice.
  • the luciferase activity was determined using a kit from Promega (Madison, WI), and a luminometer from Berthold Systems, Inc. (Pittsburgh, PA). Briefly, the lungs were placed in 500 ⁇ l of lysis buffer (Promega kit) and homogenized for 20 seconds with a tissue homogenizer (Brinkman Polytron). Samples were centrifuged in a microcentrifuge for 30 minutes at 14 000 g at 4°C. The protein concentrations were determined using the Bradford reagent (BioRad, NY) A sample containing 100 ⁇ g of protein from the supernatant fraction was used in the luciferase assay. Luciferase activity in each sample was normalized to the relative Ught units per milligram of extracted protein.
  • Example 3 Surfactant improves deUvery of free nucleic acid
  • compositions containing 50 ⁇ g of plasmid DNA and varying amounts of surfactant were provided by oral tracheal administration.
  • a representative surfactant, Survanta was administered into BALB/c mice at 10, 12, 14 and 16 mg ml.
  • the lungs were coUected at 24 hours, and protein concentration and luciferase activity were ascertained. As seen in Table 3, higher levels of expression were achieved in the presence of Survanta as opposed to control.
  • This example demonstrates the different levels of gene expression over time for compositions containing free nucleic acid and a surfactant, Survanta.
  • the results presented in Table 4 show, the levels of gene expression were increased with the addition of surfactant after 24, 48 and 72 hours over DNA that was administered without surfactant.
  • the experiments were conducted by mixing 50 ⁇ g of plasmid DNA with 14 mg/ml Survanta to a final volume of 100 ⁇ l. This mixture was administered by oral tracheal instillation to BALB/c mice. Protein concentration and luciferase assays were performed. N DNA is DNA alone and DNA/Su is DNA with surfactant.
  • This example demonstrates how to optimize the volume of administration.
  • the quantity of vector and surfactant were held constant, and the volume of composition was varied.
  • Example 6 Duration of gene expression upon a single oral tracheal administration of free nucleic acid
  • mice were harvested at tune points 6, 12, 24, 48 and 72 hours and 6, 10, 14, 21 and 28 days.
  • Example 7 Repeated deUvery of free nucleic acid surprisingly results in expression levels that can be repeatedly achieved, with no Umiting inflammatory or immune response
  • mice received 10 mg/kg dexamethasone, intraperitoneaUy. AdditionaUy, the mice received 10 mg/kg dexamethosone (ip) thirty minutes prior to plasmid deUvery on days 4, 8, 12, 16, 20 and 24. Animals were sacrificed 4 days foUowing plasmid administration and protein concentration and luciferase assays were performed. Results are presented below in Figure 1 and are reported as mean +/- standard deviation. Data points represent five animals each, except day 24, which utilized only four animals.
  • Example 10 Tissue distribution of a secreted transgene product
  • This example demonstrates the distribution of a protease inhibitor transgene product, foUowing oral-tracheal instiUation of a plasmid, versus intravenous administration and administration with purified protein.
  • These data show that the transgene deUvers simUar amounts of product as direct deUvery of the protein. Because the protein is constantly made by the transgene, overall levels do not decrease over time as is the case with the protein, providing a clear benefit of the present methods. Data were coUected twelve hours after oral-tracheal or intravenous administration.
  • DOTAP l,2-dioleoyoxy-3-(trimethylammonio) propane
  • pCfliSLPI cholesterol complexed pCfliSLPI
  • IV intravenous
  • Forty five mg DOTAP and 25 mg cholesterol were mixed in cyclohexane and lyophilized to dryness.
  • Double dist ⁇ led water was added to the Upid cake to give a final concentration of 10 mg/ml of cationic Upid (i.e., not including the cholesterol component) and aUowed to hydrate at 70°C for 1 hour.
  • the DOTAP/cholesterol dispersion was extruded through 100 nm pore carbonate membranes (Avanti Polar Lipids, Inc.).
  • the resulting size of the DOTAP-cholesterol dispersion was 150-200 nm.
  • Intravenous (IN) injections 200 ⁇ l were performed using 60 ⁇ g pCfliSLPI complexed with DOTAP-cholesterol at a 4 to 1 (positive to negative) charge ratio.
  • the Upoplexes were prepared immediately prior to IV injection by adding the 60 ⁇ g of plasmid, dissolved in 100 ⁇ l 10% glucose, to 100 ⁇ l of 5.1 mg/ml DOTAP-cholesterol dispersion in ddH 2 O.
  • bronchoalveolar lavage (BAL) was performed by annulating the trachea with a silastic catheter and slowly injecting 700 ⁇ l of PBS.
  • Lungs were coUected and placed with 500 ⁇ l lysis buffer in lysing matrix tubes (BIO 101, Vista, CA).
  • the lungs were homogenized for 20 seconds at speed 6.0 in a Fast Prep FP120 (BIO 101).
  • the homogenate was microcentrifuged at 14 000 g at 4°C for 30 minutes. AdditionaUy, blood was coUected, aUowed to clot and the sera were separated. The recovered fluids were then centrifuged at 1500 rpm for 10 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP00991274A 1999-12-28 2000-12-27 Verfahren zur erreichung einer persistierenden transgenexpression Withdrawn EP1242608A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47301899A 1999-12-28 1999-12-28
US473018 1999-12-28
PCT/EP2000/013297 WO2001048231A2 (en) 1999-12-28 2000-12-27 Method of achieving persistent transgene expression

Publications (1)

Publication Number Publication Date
EP1242608A2 true EP1242608A2 (de) 2002-09-25

Family

ID=23877847

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00991274A Withdrawn EP1242608A2 (de) 1999-12-28 2000-12-27 Verfahren zur erreichung einer persistierenden transgenexpression

Country Status (8)

Country Link
EP (1) EP1242608A2 (de)
JP (1) JP2003522133A (de)
CN (2) CN1310679C (de)
AU (1) AU3164801A (de)
CA (1) CA2395544A1 (de)
IL (1) IL150485A0 (de)
NZ (1) NZ531527A (de)
WO (1) WO2001048231A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7713695B2 (en) * 2005-02-07 2010-05-11 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
CN113384705A (zh) * 2021-06-28 2021-09-14 西南大学 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
ES2116269T3 (es) * 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
CN1209068A (zh) * 1995-10-23 1999-02-24 海欧制药澳大利亚有限公司 作为基因治疗所用的dna载体的透明质酸及治疗异常视网膜血管化的vegf反义dna
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
DE69834038D1 (de) * 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0148231A2 *

Also Published As

Publication number Publication date
AU3164801A (en) 2001-07-09
IL150485A0 (en) 2002-12-01
JP2003522133A (ja) 2003-07-22
CN1310679C (zh) 2007-04-18
CA2395544A1 (en) 2001-07-05
NZ531527A (en) 2005-10-28
CN1433477A (zh) 2003-07-30
WO2001048231A2 (en) 2001-07-05
CN101011584A (zh) 2007-08-08
WO2001048231A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
Brigham et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy
Geest et al. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone
JP2004500880A (ja) 肝臓特異的な遺伝子発現カセット、及びその使用法
CN102802659B (zh) Lcat治疗贫血和红细胞功能障碍的用途
Gautam et al. Delivery systems for pulmonary gene therapy
WO1996014837A1 (en) Gene therapy for hypercholesterolemia
US20240269255A1 (en) Hpv infectious disease vaccine
EP1242608A2 (de) Verfahren zur erreichung einer persistierenden transgenexpression
US6365575B1 (en) Gene delivery and expression in areas inaccessible to direct protein delivery
US20010014319A1 (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
US7074399B2 (en) Treatment of inflammation with p20
US20030148975A1 (en) Method of achieving persistent transgene expression
AU2004240187A1 (en) Method of achieving persistent transgene expression
EP1183361B1 (de) Gentherapy von lungenkrankheiten
WO1996030051A1 (en) Use of surfactants for introducing genetic material into lung cells
WO2006136963A2 (en) Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract
Bigger et al. Perspectives on gene therapy for cystic fibrosis airway disease
WO2004039397A1 (en) Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1-antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds
TW202521698A (zh) 用於目標基因的表現匣及其應用
WO2021222175A1 (en) Methods for suppressing immune response in gene therapy
Flotte Approach to pulmonary diseases with a genetic basis
Brigham et al. Rationale for the use of Gene Therapy for Critical Illness
Carter The Respiratory System as a Platform for Gene Delivery
CARTER 12 The Respiratory System as Delivery
HK1091127B (en) Compounds and methods for downregulating the effects of tgf-beta

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

Owner name: NOVARTIS PHARMA GMBH

17Q First examination report despatched

Effective date: 20030910

17Q First examination report despatched

Effective date: 20030910

17Q First examination report despatched

Effective date: 20030910

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080701